Phaseline

Companies › Crinetics Pharmaceuticals

Crinetics Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 2 Phase 3, 2 Phase 2, 2 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Atumelnant
Melanocortin 2 receptor (MC2R/ACTH receptor) antagonist
MC2RPhase 3Congenital Adrenal HyperplasiaMay 2027
Paltusotine
Somatostatin receptor 2 agonist
SSTR2Phase 3Carcinoid SyndromeAug 2027
CRN09682
SST2-targeting therapy for neuroendocrine and solid tumors
–Phase 1SST2-positive Neuroendocrine NeoplasmsAug 2027
CRN04894
ACTH receptor antagonist
ACTHLYPhase 1Cushing Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05804669CRN04894Phase 1Cushing SyndromeMetabolic and endocrineAug 2026
NCT07144163AtumelnantPhase 3Congenital Adrenal HyperplasiaGenitourinaryMay 2027
NCT07129252CRN09682Phase 1SST2-positive Neuroendocrine NeoplasmsOncologyAug 2027
NCT07087054PaltusotinePhase 3Carcinoid SyndromeOncologyAug 2027
NCT06712823AtumelnantPhase 2Congenital Adrenal HyperplasiaGenitourinaryJul 2029
NCT07159841AtumelnantPhase 2Congenital Adrenal HyperplasiaGenitourinaryMar 2030

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MC2R (1) SSTR2 (1) ACTHLY (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio ITM Solucin Nanjing Chia-tai Tianqing Pharmaceutical Orano Med Camurus Jiangsu HengRui Medicine Advanced Accelerator Applications

Companies built like this

Debiopharm International RayzeBio Biocity Biopharmaceutics Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Jiangsu Alphamab Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.